Log in
Fluorescence lifetime research since 1993 in Strathclyde's Photophysics Group led by Prof. David Birch contributed to the success of the University spin-out company IBH (Imhof, Birch, Hallam), and its successful merger with the £1Bn multinational company Horiba. The Strathclyde research has helped Horiba to be, since 2008, the market-leading supplier of fluorescence spectrometers, which comprise steady-state, lifetime and hybrid instruments. The commercial success of the company has led to economic benefits and employment. Through production of an improved spectrometry product range, the Strathclyde research has also facilitated multidisciplinary molecular and materials research globally, across Industry, Government and University sectors, bringing benefits to diverse disciplines such as life sciences, healthcare, chemistry, and nanotechnology.
Fluorescent ligand technologies developed by Professor Hill and Dr Briddon in the Pharmacology research group, in collaboration with Professor Kellam in the School of Pharmacy, permitted biophysical analysis of G-protein coupled receptors (GPCRs) at the individual cell and molecule level for the first time. The technologies have been commercialised through the spin-out business, CellAura Technologies (and their distributors Abcam, Sigma-Aldrich and others), generating revenues and making the products available to researchers and drug discovery communities worldwide. Custom product developments with global pharmaceutical companies and drug screening reagent providers have generated further partnership revenues and technology benefits. Nottingham-trained researchers are now employed worldwide, broadening the technology's impacts.
A commercial continuous glucose sensor/monitor that provides real time data has been developed by GlySure, a venture capital funded company founded on the basis of Bath chemistry. The sensor enables Tight Glycaemic Control (TGC) for control of glucose levels in patients in Intensive Care Units (ICUs), reducing severe hypoglycaemia, glycaemic variability and the nursing burden, maximising both patient and economic benefit. This has led to (i) £13.5M investment in the company GlySure Ltd directly for development of the system based on the Bath chemistry and (ii) successful results from full clinical trials of the device, involving more than 200 ICU patients, prior to CE approval and launch in the EU.
The development of microelectronic sensor arrays for biological applications, pioneered at the University of Glasgow, is central to a unique gene sequencing system developed by Ion Torrent. The Ion Torrent personal genome machine is a bench-top system that, compared to optically mediated technologies, is cheaper and easier to use. Ion Torrent was founded in 2007 and bought by Life Technologies in 2010 for $725M; they, in turn, were bought by Thermo Fisher for $13Bn, citing Ion Torrent as a motivation. Ion Torrent now has 62% of the bench-top sequencing market, estimated to be worth $1.3Bn in 2012.
Research by the School of Pharmacy has underpinned the development of fluorescent ligand probes that have opened-up new pathways in drug discovery. These ligands have been commercialised through the formation of the spin-out company CellAura Technologies Ltd, and have been made globally available through a number of distributer agreements. Customers include pharmaceutical companies (e.g. Pfizer, AstraZeneca), drug discovery biotechs (e.g. Addex, Heptares) and drug discovery technology providers (e.g. CisBio). These ligands provide alternatives to the use of radio-ligands, giving more informative and safer solutions for industrial drug discovery. This has, for example, enabled: a new direction in G protein-coupled receptor research at Novartis Pharmaceuticals UK Ltd; validation of Promega Corporation's new drug-binding assay; and superior performance in the establishment of cell lines at inSCREENex GmbH.